摘要
目的探讨依那西普治疗幼年特发性关节炎的临床效果和安全性。方法对32例幼年特发性关节炎患儿皮下注射依那西普每次0.4 mg.kg-1,每周2次,记录患儿治疗前后的症状、体征和实验室指标,观察治疗的不良反应。结果依那西普治疗6个月后患儿的泼尼松用量显著降低,并有8例患儿停用泼尼松治疗;患儿的外周血白细胞计数(WBC)、ESR、CRP以及血清蛋白(SF)较之治疗前均显著下降(P<0.01);多关节型患儿的平均受累关节数由(6.5±1.2)个降至(1.4±0.3)个,治疗中未见有严重不良反应发生。结论依那西普对幼年特发性关节炎有显著临床疗效,不良反应小且发生率低,值得临床推广。
Objective To observe the clinical effect of etanercept on juvenile idiopathic arthritis.Methods 32 cases of patients with juvenile idiopathic arthritis were selected and treated by etanercept subcutaneous injection 0.4 mg·kg-1）,twice a week.The symptoms,laboratory index and adverse effect were observed.Results Six months after the treatment by etanercept,the dosage of prednisone were reduced and eight cases stopped taking prednisone.The values of WBC,ESR,CRP and SF were reduced significantly（P0.01）.The number of involved joint was reduced from（6.5±1.2） to（1.4±0.3）.There was no serious adverse effect in the treatment.Conclusion The clinical effect of etanercept on juvenile idiopathic arthritis is significant and the incidence of adverse effect is low.It is worthy of generalization.
出处
《安徽医药》
CAS
2013年第1期122-123,共2页
Anhui Medical and Pharmaceutical Journal
